Cellectar Biosciences, Inc. Fair Value Adjustment of Warrants
Cellectar Biosciences, Inc. (CLRB) reported Fair Value Adjustment of Warrants of -$132.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-13
- Cellectar Biosciences, Inc. fair value adjustment of warrants for the quarter ending 2026-06-30 was -$132.00K.
- Cellectar Biosciences, Inc. fair value adjustment of warrants for the quarter ending 2026-03-31 was -$77.00K, a 122.65% decline year-over-year.
- Cellectar Biosciences, Inc. fair value adjustment of warrants for the quarter ending 2025-12-31 was -$297.83K.
- Cellectar Biosciences, Inc. fair value adjustment of warrants for the quarter ending 2025-09-30 was -$294.28K.
- Cellectar Biosciences, Inc. fair value adjustment of warrants for fiscal 2025 was -$753.71K.
- Cellectar Biosciences, Inc. fair value adjustment of warrants for fiscal 2024 was -$13.79M, a 464.25% decline from fiscal 2023.
- Cellectar Biosciences, Inc. fair value adjustment of warrants for fiscal 2023 was $3.79M.
- Cellectar Biosciences, Inc. fair value adjustment of warrants for fiscal 2022 was -$3.63M.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 3 month as first filed | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 9 month as first filed | Fair Value Adjustment of Warrants 12 month | Fair Value Adjustment of Warrants 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$132.00K 10-Q · filed 2026-08-13 | -$209.00K 10-Q · filed 2026-08-13 | -$506.83K derived: sum of 3 quarters · filed 2026-08-13 | -$801.11K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | -$77.00K 10-Q · filed 2026-05-14 | -$374.83K derived: sum of 2 quarters · filed 2026-05-14 | -$669.11K derived: sum of 3 quarters · filed 2026-05-14 | -$1.17M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | -$297.83K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$592.11K derived: sum of 2 quarters · filed 2026-03-04 | -$1.09M derived: sum of 3 quarters · filed 2026-08-13 | -$753.71K 10-K · filed 2026-03-04 | |||
| 2025-09-30 | -$294.28K 10-Q · filed 2025-11-13 | -$795.87K derived: sum of 2 quarters · filed 2026-08-13 | -$455.87K 10-Q · filed 2025-11-13 | -$10.67M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | -$501.60K 10-Q · filed 2026-08-13 | -$161.60K 10-Q · filed 2026-08-13 | -$10.37M derived: sum of 3 quarters · filed 2026-08-13 | -$16.46M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $340.00K 10-Q · filed 2026-05-14 | -$9.87M derived: sum of 2 quarters · filed 2026-05-14 | -$15.96M derived: sum of 3 quarters · filed 2026-05-14 | -$28.42M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2024-12-31 | -$10.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$16.30M derived: sum of 2 quarters · filed 2026-03-04 | -$28.76M derived: sum of 3 quarters · filed 2026-03-04 | -$13.79M 10-K · filed 2026-03-04 | |||
| 2024-09-30 | -$6.09M 10-Q · filed 2025-11-13 | -$18.54M derived: sum of 2 quarters · filed 2025-11-13 | -$3.58M 10-Q · filed 2025-11-13 | -$8.05M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | -$12.46M 10-Q · filed 2025-08-14 | $2.50M 10-Q · filed 2025-08-14 | -$1.96M derived: sum of 3 quarters · filed 2025-08-14 | $5.73M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $14.96M 10-Q · filed 2025-05-13 | $9.90M 10-Q · filed 2024-05-14 | $10.49M derived: sum of 2 quarters · filed 2025-05-13 | $18.18M derived: sum of 3 quarters · filed 2025-05-13 | $20.14M derived: sum of 4 quarters · filed 2025-05-13 | ||
| 2023-12-31 | -$4.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $3.22M derived: sum of 2 quarters · filed 2025-03-13 | $5.18M derived: sum of 3 quarters · filed 2025-03-13 | $3.79M 10-K · filed 2025-03-13 | -$1.00M 10-K · filed 2024-03-27 | ||
| 2023-09-30 | $7.69M 10-Q · filed 2024-11-18 | $3.90M 10-Q · filed 2023-11-13 | $9.65M derived: sum of 2 quarters · filed 2024-11-18 | $8.25M 10-Q · filed 2024-11-18 | $3.90M 10-Q · filed 2023-11-13 | $6.62M derived: sum of 4 quarters · filed 2024-11-18 | |
| 2023-06-30 | $1.96M 10-K/A · filed 2024-10-29 | $566.62K 10-K/A · filed 2024-10-29 | -$1.07M derived: sum of 3 quarters · filed 2024-10-29 | -$1.37M derived: sum of 4 quarters · filed 2024-10-29 | |||
| 2023-03-31 | -$1.39M 10-K/A · filed 2024-10-29 | -$3.02M derived: sum of 2 quarters · filed 2024-10-29 | -$3.32M derived: sum of 3 quarters · filed 2024-10-29 | -$5.12M derived: sum of 4 quarters · filed 2024-10-29 | |||
| 2022-12-31 | -$1.63M derived: 10-K/A 12 month − 10-K/A 9 month · filed 2024-10-29 | -$1.93M derived: sum of 2 quarters · filed 2024-10-29 | -$3.73M derived: sum of 3 quarters · filed 2024-10-29 | -$3.63M 10-K/A · filed 2024-10-29 | |||
| 2022-09-30 | -$300.00K 10-K/A · filed 2024-10-29 | -$2.10M derived: sum of 2 quarters · filed 2024-10-29 | -$2.00M 10-K/A · filed 2024-10-29 | ||||
| 2022-06-30 | -$1.80M 10-K/A · filed 2024-10-29 | -$1.70M 10-K/A · filed 2024-10-29 | |||||
| 2022-03-31 | $100.00K 10-K/A · filed 2024-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |